...
首页> 外文期刊>Medicine. >Microwave ablation combined with transcatheter arterial chemoembolization is effective for treating unresectable hepatoblastoma in infants and children
【24h】

Microwave ablation combined with transcatheter arterial chemoembolization is effective for treating unresectable hepatoblastoma in infants and children

机译:微波消融联合经导管动脉化疗栓塞治疗婴儿和儿童不可切除的肝母细胞瘤有效

获取原文

摘要

The present study is to evaluate the feasibility and efficacy of microwave ablation (MWA) combined with transcatheter arterial chemoembolization (TACE) in the treatment for unresectable hepatoblastoma in infants and children . A total of 17 patients with PRETEXT stage III and IV hepatoblastoma that was unresectable by conventional resection were included in the present study. The patients were treated with TACE, MWA, and chemotherapy. All cases were diagnosed by computed tomography (CT) and liver tumor biopsy before TACE procedure. All patients received 2 courses of TACE and 1 to 2 times of MWA. Finally, several cycles of chemotherapy were arranged. Among the 17 patients, 14 were alive and had normal alpha-fetoprotein (AFP) levels. The other 3 patients died from tumor progression. The follow-up periods ranged from 10 to 68 months. Complete ablation was achieved in the 14 patients (14/17, 82.35%). Most patients were well tolerated during the whole course except for 1 patient with pneumonedema after TACE and another 1 with biloma after MWA. No marked chemotherapeutic agent-induced toxicity occurred. After chemotherapy or TACE, transient blood indicators and symptoms were observed as follows: myelosuppression, abnormal liver function, gross hematuria, fever, and abdominal pain. Transient symptoms after MWA were fever, abdominal pain, and massive gross hematuria. The present study demonstrates that MWA combined with TACE is a safe and effective method for treating unresectable hepatoblastoma in infants and children with controllable side effects.
机译:本研究旨在评估微波消融(MWA)联合经导管动脉化学栓塞(TACE)治疗婴儿和儿童不可切除的肝母细胞瘤的可行性和疗效。本研究共包括17例不能通过常规切除术切除的PRETEXT III和IV期肝母细胞瘤患者。患者接受了TACE,MWA和化学疗法治疗。所有病例均在TACE术前通过计算机断层扫描(CT)和肝肿瘤活检确诊。所有患者均接受2疗程的TACE和1至2倍的MWA。最后,安排了几个化疗周期。在这17例患者中,有14例还活着并且具有正常的甲胎蛋白(AFP)水平。另外3例患者死于肿瘤进展。随访期为10到68个月。 14例患者完全消融(14/17,82.35%)。大多数患者在整个疗程中耐受良好,除了1例TACE后出现肺水肿和1例MWA之后伴胆汁瘤。没有明显的化学治疗剂诱导的毒性发生。化疗或TACE后,观察到以下短暂血液指标和症状:骨髓抑制,肝功能异常,严重血尿,发烧和腹痛。 MWA后的短暂症状为发烧,腹痛和大量肉眼血尿。本研究表明,MWA与TACE联合使用是一种治疗副作用的可治小儿不可切除肝母细胞瘤的安全有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号